Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of “Buy” from Brokerages

Kymera Therapeutics, Inc. (NASDAQ:KYMR) has been given a consensus recommendation of “Buy” by the twenty-two analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, nineteen have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have covered the stock in the last year is $112.80.

Several research analysts have weighed in on the company. Citigroup boosted their price target on Kymera Therapeutics from $80.00 to $110.00 and gave the company a “buy” rating in a report on Tuesday. Jefferies Financial Group upped their target price on Kymera Therapeutics from $73.00 to $122.00 and gave the company a “buy” rating in a research note on Tuesday. Stephens raised their price target on Kymera Therapeutics from $65.00 to $110.00 and gave the stock an “overweight” rating in a research note on Thursday. Mizuho lifted their price target on Kymera Therapeutics from $81.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday. Finally, Morgan Stanley increased their price objective on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the stock an “overweight” rating in a report on Tuesday.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, Director Bruce Booth sold 229,809 shares of Kymera Therapeutics stock in a transaction on Wednesday, December 10th. The shares were sold at an average price of $91.73, for a total value of $21,080,379.57. Following the transaction, the director owned 686,477 shares in the company, valued at $62,970,535.21. This trade represents a 25.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jared Gollob sold 59,576 shares of the business’s stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $61.42, for a total transaction of $3,659,157.92. Following the sale, the insider directly owned 109,992 shares of the company’s stock, valued at $6,755,708.64. This represents a 35.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 597,805 shares of company stock valued at $46,839,199 over the last 90 days. 16.01% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in KYMR. Siren L.L.C. grew its position in Kymera Therapeutics by 9.1% in the first quarter. Siren L.L.C. now owns 3,240,313 shares of the company’s stock valued at $88,687,000 after acquiring an additional 270,580 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Kymera Therapeutics by 26.3% in the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 107,438 shares of the company’s stock valued at $4,689,000 after purchasing an additional 22,392 shares during the period. Rhumbline Advisers boosted its stake in shares of Kymera Therapeutics by 9.0% in the first quarter. Rhumbline Advisers now owns 69,928 shares of the company’s stock valued at $1,914,000 after purchasing an additional 5,771 shares during the period. Atika Capital Management LLC acquired a new stake in Kymera Therapeutics during the 2nd quarter valued at $6,398,000. Finally, Farther Finance Advisors LLC grew its holdings in Kymera Therapeutics by 642.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 624 shares of the company’s stock valued at $27,000 after purchasing an additional 540 shares in the last quarter.

Kymera Therapeutics Trading Up 2.1%

NASDAQ:KYMR opened at $89.68 on Friday. Kymera Therapeutics has a 12-month low of $19.44 and a 12-month high of $103.00. The firm has a market cap of $6.45 billion, a price-to-earnings ratio of -24.98 and a beta of 2.28. The company’s 50-day moving average is $64.77 and its two-hundred day moving average is $52.02.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Tuesday, November 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). The firm had revenue of $2.76 million during the quarter, compared to analyst estimates of $23.15 million. Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. On average, equities research analysts forecast that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.